(BLRX)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
| Name | Position |
|---|---|
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations |
| Mr. Philip A. Serlin CPA, M.B.A. | Chief Executive Officer |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director |
| Ms. Mali Zeevi CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-23 | S-8 | zk2634171.htm |
| 2025-11-24 | 6-K | zk2534058.htm |
| 2025-11-17 | 6-K | zk2534026.htm |
| 2025-09-29 | 6-K | zk2533810.htm |
| 2025-08-14 | 6-K | zk2533581.htm |
| 2025-06-30 | 6-K | zk2533386.htm |
| 2025-05-30 | 6-K | zk2533302.htm |
| 2025-05-27 | 6-K | zk2533265.htm |
| 2025-05-23 | 6-K | zk2533250.htm |
| 2025-03-31 | 6-K | zk2532945.htm |